anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain the subject pharmaceutical preparation, containing sulfated acidic mucopolysaccharides, sulfated dextran or a salt thereof as an active ingredient and capable of manifesting strong antiinflammatory actions, useful for preventing and treating adult respiratory distress syndrome, etc., and having a new mode of action. CONSTITUTION: This antiinflammatory agent contains sulfated acidic mucopolysaccharides (preferably sulfated hyaluronic acid), sulfated dextran or a salt thereof as an active ingredient. The active ingredient is preferably mixed with a diluent or an excipient such as water or ethyl alcohol to prepare a solution or a suspension, which is then preferably parenterally administered. When the sulfated hyaluronic acid is prepared as a parenteral injection, the sulfated hyaluronic acid is preferably regulated to 0.05-1(wt./vol.)% in a physiological saline solution. The dose of the sulfated hyaluronic acid as the active ingredient is preferably 0.1-10mg/kg in the case of the intravenous injection.  Furthermore, the sulfated hyaluronic acid is usually obtained by sulfating hyaluronic acid originating from a natural product; however, a sulfuric acid- trimethylamine complex is preferably used as a sulfating agent.
A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
This randomized study compares effects of duration vs. velocity-based TM training regimens on fitness and ambulatory function in chronic stroke patients. Phase 1 - patients are screened (Mini Mental Status, CESD for depression, alcohol intake survey) and undergo routine medical and CV evaluations and blood labs in VA RRDC Assessment Clinic to establish medical eligibility. Standard neurological evaluations (NIH Stroke Scale, Modified Asworth Spasticity Scale, range of motion and manual motor testing) and review of imaging records assess neurological eligibility, deficit profiles and stroke subtypes. Physician supervised treadmill tolerance test and peak effort constant velocity exercise stress test with vital signs monitoring determine treadmill safety, functional eligibility to participate (must walk 3 minutes at 0.2 MPH with handrail support), and cardiopulmonary safety in response to strenuous exertion. Eligible candidates undergo baseline testing (phase 2) including measures of fitness (VO2 peak, gait economy), ambulatory function and BOLD fMRI of knee movement. Phase 3 - 6 months TM training with either velocity or duration based progression, followed by Phase 4 -repeat of fitness and ambulatory function tests after 3 months, and Phase 5 - repeat of all baseline tests after 6 months training
Stroke is the leading cause of adult disability and costs U.S. taxpayers \>$60 billion annually. Interventions designed to educate patients to seek treatment sooner when a stroke occurs may increase low rates of treatment with thrombolysis (current rates 3% national average). Thrombolysis can increase the odds of minimal to zero disability from stroke if emergency medical system response times and in-hospital response times are optimized (maximum time from symptom onset to intravenous thrombolysis is 4.5 hours). Black and Hispanic Americans have higher stroke incidence compared to Whites and are less likely to receive thrombolysis for acute stroke. The latency to hospital arrival is largely dependent on patients' recognition of stroke symptoms, and immediate presentation to the emergency department. The investigators have found very low stroke literacy rates among Blacks and Hispanics compared to Whites, which may, in part, be responsible for disparities in acute stroke treatment.
Autoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n = 19), primary biliary cholangitis (PBC, n = 15), and primary sclerosing cholangitis (PSC, n = 6). Healthy individuals (n = 24) and patients with metabolic dysfunction-associated steatotic liver disease (MASLD, n = 18) were included as controls. Blood samples were collected during a 120-min oral glucose tolerance test. We measured the concentrations of glucose, C-peptide, insulin, glucagon, and the two incretin hormones, glucose insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). We calculated the homeostasis model assessment of insulin resistance (HOMA-IR), whole body insulin resistance (Matsuda index), insulin clearance, and insulinogenic index. All patient groups had increased fasting plasma glucose and impaired glucose responses compared with healthy controls. Beta-cell secretion was increased in AIH, PBC, and MASLD but not in PSC. Patients with AIH and MASLD had hyperglucagonemia and hepatic, as well as peripheral, insulin resistance and decreased insulin clearance, resulting in hyperinsulinemia. Patients with autoimmune liver disease had an increased GIP response, and those with AIH or PBC had an increased GLP-1 response. Our data demonstrate that the mechanism underlying glucose disturbances in patients with autoimmune liver disease differs from that underlying MASLD, including compensatory incretin responses in patients with autoimmune liver disease. Our results suggest that glucose disturbances are present at an early stage of the disease.NEW & NOTEWORTHY Patients with autoimmune liver disease but without overt diabetes display glucose disturbances early on in their disease course. We identified pathophysiological traits specific to these patients including altered incretin responses.
ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.
<P>PROBLEM TO BE SOLVED: To perform high-accuracy information extraction from a document in an individual field, e.g., a medical document such as an image reading report.  <P>SOLUTION: A medical term extraction part 11 extracts a medical term by use of an extraction rule or a medical vocabulary dictionary stored in a medical vocabulary resource holding part 12. An initial rule application part 14 takes out a medical term relation extraction rule stored in an initial rule holding part 13, applies it to the medical document, and extracts a vocabulary of a TARGET portion in each rule. An expansion rule creation part 15 acquires a combination between an acquired medical category and the vocabulary having some certain frequency or above among the vocabularies, and extracts an expansion rule. An information extraction part 17 performs the information extraction by use of a set of an initial rule stored in the initial rule holding part 13 and the expansion rule held in an expansion rule holding part 16.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
Single bilateral injection into three standardized points of the masseter muscles and two of the anterior temporalis muscle. The total dose administered is 100 U (10 U/point) which is dissolved in 1 mL of isotonic saline. Thus, 0.1 ml of botulinum toxin solution is injected in each point.
Anxiety is a common, but understudied complaint in midlife women, and increases during the menopausal transition. Changes in estrogen are dramatic during the menopausal transition, and indirect data suggest a potential role for estrogen, particularly estrogen receptor beta, in mediating anxiety. Two subtypes of the estrogen receptor, alpha and beta (ER-alpha and ER-beta), appear to be critically involved in the expression of anxiety in females. Compounds that preferentially target ER-beta, including plant-derived estrogens (phytoestrogens), lower both anxiety behaviors and responsivity to discrete stressors, including social stress, in laboratory animals. The primary aim of this proposal is to carry out the first study to translate these preclinical studies to humans by comparing and contrasting of the effects of phytoestrogens, estradiol, and placebo on daily anxiety and responses to moderate psychosocial stress in the laboratory. As second focus is emotional and non-emotional cognition. This focus stems from evidence that estrogen can protect against the negative impact of glucocorticoids on memory. These aims will be accomplished in a 12-week randomized placebo-controlled, clinical trial comparing three treatments: 1) a phytoestrogen supplement (Novasoy® 400, 55 mg tablet twice daily); 2) oral estradiol (1 mg/daily; plus 10 mg medroxyprogesterone acetate at study end 10 for 10 days); and 3) placebo (identical appearing tablets twice daily). The enrollment target is 120 healthy women in the menopausal transition (40 per group). To measure anxiety, women will complete the State-Trait Anxiety Inventory (STAI). To measure responsivity to psychosocial stress, parallel forms of the Trier Social Stress Test, a widely used laboratory induction that involves unanticipated public speaking and social evaluative fear, will be used to induce moderate psychosocial stress before and after treatment. At both laboratory sessions, measures of subjective stress (STAI), cortisol, and emotional memory performance will be obtained at multiple points during a control condition and during the psychosocial stress condition. Lastly, we will measure treatment effects on measures of verbal memory.
When students approach the table, research assistants will ask them to choose their favorite kind of candy from an assortment. They will ask the subjects to rate their craving for the candy before they taste it. After they try the candy, the research assistants will ask them to rate its palatability. Then they will rate their craving for another piece of candy. A research assistant will flip a coin to determine whether the subject will receive Crave Crush or placebo. While the Crave Crush or placebo is dissolving in the mouth, the students will fill out a short questionnaire with an identification number. The questionnaire will ask for their age, gender, ethnicity, approximate height and weight, and a few questions about their dietary habits.

After the tablet dissolves, research assistants will ask the students to rate their craving for another piece of candy. Research assistants will ask participants if they would like another piece of candy and have them assess palatability again. The process of offering a piece of candy and asking subjects to rate palatability will occur up to five times. Finally, subjects will be asked if they would like to take a few pieces of candy for the road and if they say yes, the number of pieces they take with them will be noted. The study activities should last no more than 5-10 minutes per participant.
A cross-sectional study was carried out from September 20 to December 5, 2022, on adult patients who visited the surgical outpatient department at the Hiwotfana Comprehensive Specialized Hospital and Jugol Regional Hospital in Eastern Ethiopia. All adult patients who visited the surgical outpatient department of each hospital were enrolled in the study using a systematic random sampling technique with skipping intervals of two until the calculated sample size was obtained, which is 403. Data collection was accomplished through medical record reviews of patients and face-to-face interviews. The data were analyzed by the Statistical Package for Social Science version 26 software. Both descriptive and inferential statistics were conducted, and the results were presented in text, graphs, and tables. A Chi-square test was calculated, and an Odds ratio for the strength and directions of association was used with a 95% confidence interval and a P-value of \<0.05 to be considered statistical. This investigation determined the overall magnitude of external abdominal wall hernias in the study area as well as the types of external abdominal hernias. At the conclusion of the investigation, each significant associated factor for an external abdominal hernia was identified.
A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
This is an open-label Phase 1 dose escalation study of OMP-21M18 in subjects with previously treated solid tumors for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit. Up to 30 subjects will be enrolled at up to 4 centers. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy. No formal interim analyses will be performed. Prior to enrollment, subjects will undergo screening to determine study eligibility. Upon enrollment, subjects will receive weekly intravenous (IV) infusions of OMP-21M18 for 9 weeks. After 9 weeks of treatment, subjects will be assessed for disease status. If there is no evidence of disease progression or if the tumor is smaller, then subjects may continue to receive IV infusions of OMP-21M18 every other week until disease progression.

Dose escalation will be conducted to determine the maximum tolerated dose (MTD). The dose levels of OMP 21M18 will be 0.5, 1.0, 2.5, 5, and 10 mg/kg administered IV weekly for 9 doses. No dose escalation or reduction will be allowed within a dose cohort. The dose may be administered at any time during the day. Three subjects will be treated at each dose level if no dose-limiting toxicities (DLTs) are observed. If 1 of 3 subjects experience a DLT, that dose level will be expanded to 6 subjects. If 2 or more subjects experience a DLT, no further subjects will be dosed at that level and 3 additional subjects will be added to the preceding dose cohort unless 6 subjects have already been treated at that dose level. Subjects will be assessed for DLTs from the time of the first dose through 7 days after administration of the 4th dose, but prior to administration of the 5th dose (i.e., Days 0-28). Dose escalation, if appropriate, will occur after all subjects in a cohort have completed their Day 28 DLT assessment.
Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change "experiments" designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis.
One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
FIELD: food industry. ^ SUBSTANCE: invention relates to grape extracts and their production methods. Alternatively the method, according to the invention, envisages contact of a material (chosen from the group consisting of whole grapes, grape stones, grape refuses and their mixture) with water at a temperature of about 140-212F to produce the initial grape extract and treating the initial grape extract with a pectolytic enzyme during from about four to five days at a temperature of about 80-120F to produce the polyphenolic grape extract. Alternatively the method, according to the invention, envisages production of the initial aqueous grape extract and treating the extract with yeast, bacteria, fungi and their mixtures at temperature of about 70-100F to produce the polyphenolic grape extract. Alternatively the method, according to the invention, envisages production of the initial aqueous grape extract and treating it with a tannase enzyme at a temperature of about 70-100F to produce the polyphenolic grape extract. The purified polyphenolic grape extract, according to the invention, contain about or less than 2 wt % of terminal units of epicatechin-gallate and about or less than 12 wt % of extending units of epicatechin-gallate. ^ EFFECT: grape extracts allow to reduce blood pressure with patients suffering from prehypertonic condition or metabolic syndrome. ^ 22 cl, 3 tbl, 7 ex
Cardio-respiratory fitness (CRF) is well-established in the clinical domains as an integrative measure of the body's physiological capability and capacity to transport and utilise oxygen during controlled bouts of physical exertion. Long COVID is associated with >200 different symptoms and is estimated to affect ∼150 million people worldwide. The most widely reported impact is reduced quality of life and functional status due to highly sensitive and cyclical symptoms that manifest and are augmented following exposure to physical, emotional, orthostatic, and cognitive stimuli, more commonly known as post-exertional symptom exacerbation (PESE) which prevents millions from engaging in routine daily activities. The use of cardiopulmonary exercise testing (CPET) is commonplace in the assessment of integrated physiology; CPET will undoubtedly play an integral role in furthering the pathophysiology and mechanistic knowledge that will inform bespoke Long COVID treatment and management strategies. An inherent risk of previous attempts to utilise CPET protocols in patients with chronic disease is that these are compounded by PESE and have induced a worsening of symptoms for patients that can last for days or weeks. To do this effectively and to meet the global need, the complex multi-system pathophysiology of Long COVID must be considered to ensure the design and implementation of research that is both safe for participants and capable of advancing mechanistic understanding.
Ultra-small, substantially non-aggregated, non-crystalline particles of predetermined uniform size wich, when suspended in a liquid, contain entrapped gaseous bubbles are disclosed. These gaseous bubble particles are prepared by simultaneous co-precipitation of two compounds wherein one compound is substantially more soluble than the other in a given vehicle. When this vehicle is used for washing the co-precipitated particles, part of the soluble material is dissolved leaving a porous matrix. The porous particles then are dried and stored. The porous particles, which can be resuspended immediately prior to use, contain entrapped gas in the evacuated crevices or pores which is not displaced for a period of time because of surface tension of the suspending vehicle. The ultrasmall porous particles can be used as ultrasound contrast agents, such as ultrasound contrast agents in the blood vessels and soft tissue, including the liver, spleen, heart myocardium, kidney and brain of an animal, such as a human. The ultrasmall porous particles also can be used dry for applications where reduced weight is desirable.
Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes).
Major depressive disorder (MDD) is recognized as the most prevalent affective disorder worldwide. Metagenomic studies increasingly support a critical role for dysbiosis of gut microbiota in the development of depression. Previous studies have demonstrated that adenosine alleviates gut dysbiosis, suggesting that elevating adenosine levels could be a novel intervention for MDD; however, the mechanisms underlying this effect remain unclear. This study utilized 16S rRNA gene sequencing, fecal microbiota transplantation (FMT) and ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to test the hypothesis that increased adenosine alleviates depressive behaviors in male mice subjected to chronic social defeat stress (CSDS) through alterations to gut microbiota. The data showed that depression-susceptible (SUS) mice exhibited gut dysbiosis, and FMT from SUS mice increased depression-like behaviors in healthy recipients. In SUS mice, adenosine supplementation ameliorated both depression-like behaviors and abnormalities in gut microbiota, and co-administration of probiotics and adenosine not only mitigated depression-like behaviors but also enhanced gut barrier integrity. By including 83 depressed adolescents and 67 healthy controls, this study found that the level of short-chain fatty acids (SCFAs) in the depression group was reduced, this finding parallels reductions seen in SUS mice and in recipient mice after FMT from SUS donors. Conversely, supplementation with either adenosine or probiotics led increased SCFAs concentrations in the serum of SUS mice. These findings suggest that adenosine may alleviate depression-like behaviors in CSDS mice by modulating the gut microbiota. This effect is likely associated with increased serum SCFAs, metabolites produced by the gut microbiota, following adenosine supplementation. This article is part of the Special Issue on "Personality Disorders".
An occlusion clearing device for a patient has a housing with a motor(s) that generates repetitive motion, which is reciprocating, rotational or both. A clearing stem including a sheath that has a lumen, wherein aspiration is conducted through the sheath lumen. A wire is located in the sheath lumen and receives repetitive motion from the controller. The sheath terminates in a sheath end having at least one sheath opening. The wire terminates in a wire tip, which may be flat, helical, or tubular. The wire tip is positioned within the sheath end, in proximity to the sheath opening(s), and movement of the wire tip and/or sheath end relative to each other creates shearing forces that break up an adjacent occlusion.